A RARE ADVANCED STAGE CASE OF MEDULARY THYROID GLAND CANCER. SIGNIFICANT THERAPY OUTCOME BY AUTOLOGOUS HUMAN CANCER VACCINE AHICE, AUTOLOGOUS CANCER IMMUNOTHERAPY AHICE, FOR AUTO-IMMUNE DISEASES, AND FOR PREVENTION AS WELL.
Authors: J. Anthopoulos*, K.-H. Regele**, K.Papapolychroniadis***, D. Paramythiotis, P. Makrantonakis, J. Papapolychroniadou, L. Papaefthymiou, E. Fahantidis
*K-BIO, Institute for cell biotechnology and immunology GmbH,
** Medicinal Ordination for Immunotherapy at K-BIO Institute, Gröbenzell, Germany (till 2012),
*** First Propedeutic Surgical Clinic of Aristotle University of Thessaloniki, Greece, Department of Medical Oncology- First Medical Clinic- Aristotle University of Thessaloniki, Greece
Author: Wikipedia, Medullary thyroid gland cancer in Sonography with typical small calcifications (arrows).
Autologous Human Vaccine AHICE is a specific anti-tumour active advanced immunotherapy, according to ATMP regulation 1394/2007/EG of the EC for somatic-, cell- and gene-therapies.
The main target of cancer immunotherapy AHICE is to make possible the discovering, recognition, identification and killing* the masked cancer cells with such exprimed receptor-molecules like them on the outer membrane of healthy body cells (⇒ escape mechanisms of tumour cell DNA, cell-mimicry!) , which is the main-cause why cancer cells are able to establish themself parallel to existence of a physiological immune system.
Normally, this* is mainly hindered because of cancer-cell intelligence to develop escape mechanisms against the unique recognising- and killing-ability of body´s immune system against altered body cells pathologically.
After autologous vaccine AHICE treatment, the following apoptotic-cycle of cancer cells is succeeded by specific activation of Natural Killer Cells(NC´s), which is been controlled by the complex totality of autologous synthesised immune-response active agents in autologous plasma, including the matrix-information of recognized cancer cells (AHICE patent).
We present here a rare and interesting case of a 38 years old male patient with medulary thyroid cancer diagnosis on April 2003.
After the correct research study was performed total thyroidectomy plus neck and mediastinal nodal dissection.
Since then from the follow-up Since then from the follow-up study were discovered several recurrences and were performed additionally nodal and tumour resectional procedures on 2005, 2006 and Jan. 2007.
A right axillary plus ipsilateral supraclavicular nodal dissection was performed on October 2007. Because of repeated recurrence status AHICE immunotherapy was started on January 2008, in a series of two consecutive cycles with successful results, symptoms remission, performance status improvement and significant decrease of calcitonin plasma concentration levels⇒ REMISSION!
After completeness of AHICE immunotherapy there was indication for radical dissection which was performed on March 2009. Unfortunately the patient was succumbed suddenly from cardiorespiratory arrest one month later.
In conclusion we address the effectiveness of AHICE-immunotherapy for rare, interesting, difficult and multiregional recurrence cases of medulary thyroid cancer patients.
back → ImmunotherapyAHICE next → AutoImmuneDiseases